The median overall survival was 14.8 months for HCC patients with elevated tumor tissue CtBP2 expression (High CtBP2 Group), whereas the median overall survival was 58.3 months for HCC patients with lower CtBP2 levels in adjacent liver tissues (Low CtBP2 Group). This evidence concerns the gene CTBP2 and hepatocellular carcinoma.